The presentation highlights the Company's key achievements and recent commercial activities:
- Current negotiations with #1 global animal health company, Zoetis Inc, regarding a commercial agreement for the worldwide development, distribution and marketing of Detach(R)
- Submission of the Company's dossier to the Australian Pesticides and Veterinary Medicines Authority (APVMA), seeking regulatory approval to register Detach(R) for commercial marketing in Australia
- Preparing Detach(R) for commercial launch in the Australian market
- Revenue up 12.6% to $3.2 million, including the receipt of milestone payments under the Zoetis Research Evaluation and License Option Agreement, receipt of the 2015-16 R&D tax rebate and successful grant funding applications
The presentation also includes a status update on the Company's efforts to develop its product pipeline, extending from its core application to control diarrhoea in pigs, to human gastrointestinal conditions such as Irritable Bowel Syndrome, Inflammatory Bowel Disease and Traveller's Diarrhoea.
To view the presentation, please visit:
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anatara granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anatara is now focused on developing its human product pipeline for gastrointestinal health applications. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences Ltd